What is SanegeneBio?
SanegeneBio is a fully-integrated biotechnology enterprise specializing in the development of RNA interference (RNAi) therapeutics. Founded in 2021, the company maintains a robust international footprint with R&D operations spanning Boston, Shanghai, and Suzhou. At the core of its technological advantage is the LEAD tissue-selective RNAi delivery platform, which enables the precise targeting of disease-causing genes. The company's current pipeline is diverse, targeting high-unmet-need areas such as obesity, autoimmune nephropathies, and various cardiometabolic indications. With four experimental medicines already in clinical trials, SanegeneBio is effectively bridging the gap between foundational RNAi research and commercial-grade therapeutic application, aiming to deliver first-in-class and best-in-class solutions to a global patient population.
How much funding has SanegeneBio raised?
SanegeneBio has raised a total of $110M across 1 funding round:
Series B
$110M
Series B (2025): $110M with participation from China Biopharma, Lilly, Hillhouse, and Legend Capital
Key Investors in SanegeneBio
China Biopharma
China Biopharma Inc is a company that operates in the Pharmaceuticals industry, focusing on large-scale drug development and manufacturing.
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, and commercialization of prescription medicines across immunology and metabolic disease areas.
Hillhouse
Hillhouse is a full life-cycle private equity firm that manages capital for global institutions, with a strong focus on long-term growth in the healthcare sector.
What's next for SanegeneBio?
With the successful closure of this major strategic investment, SanegeneBio is well-positioned to scale its clinical operations and refine its proprietary delivery technology. The company's roadmap focuses on the maturation of its existing pipeline, with an emphasis on achieving key clinical readouts that will further validate the efficacy of its RNAi platform. Strategic priorities include the expansion of its R&D capabilities and the potential for future partnerships to accelerate the commercialization of its lead candidates. As the biotechnology sector continues to prioritize precision medicine, SanegeneBio's focus on tissue-selective delivery provides a distinct competitive edge, likely driving further interest from both strategic corporate partners and institutional investors in the coming fiscal periods.
See full SanegeneBio company page
